This is an author produced version of Systematic review, network meta-analysis and exploratory cost-effectiveness model of randomized trials of minimally invasive techniques versus surgery for varicose veins.

White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/119683/

Article:
Carroll, C. orcid.org/0000-0002-6361-6182, Hummel, S., Leaviss, J. orcid.org/0000-0002-5632-6021 et al. (4 more authors) (2014) Systematic review, network meta-analysis and exploratory cost-effectiveness model of randomized trials of minimally invasive techniques versus surgery for varicose veins. British Journal of Surgery , 101 (9). pp. 1040-1052. ISSN 0007-1323

https://doi.org/10.1002/bjs.9566
Title:
Minimally invasive techniques versus surgery for management of varicose veins: A systematic review and network meta-analysis of randomised clinical trials and exploratory cost-effectiveness model

Authors:
Christopher Carroll*
Silvia Hummel
Jo Leaviss
Shijie Ren
John W Stevens
Anna Cantrell
Jonathan Michaels

Addresses/Affiliations:
School of Health and Related Research (ScHARR), University of Sheffield, Regent Court, Regent Street, Sheffield, S1 4DA

Corresponding author*:
c.carroll@shef.ac.uk
Health Economics and Decision Science (HEDS), ScHARR, University of Sheffield, Regent Court 30 Regent Street Sheffield S1 4DA Tel: +44 (0)114 22 20864 Fax: +44 (0)114 27 24095

Funding:
This report was commissioned by the NIHR HTA Programme as project number 10/29/01.

Type of publication:
Review

Keywords:
Systematic review, cost-effectiveness, varicose veins, health technology assessment
Abstract

Background:
A Health Technology Assessment was conducted to evaluate the relative clinical and cost-effectiveness of minimally invasive techniques (foam sclerotherapy (FS), endovenous laser ablation (EVLA) and radiofrequency ablation (RFA)) for managing varicose veins, in comparison with traditional surgery.

Methods:
A systematic review of randomised controlled trials (RCTs) to assess the effectiveness of minimally invasive techniques compared with other treatments, principally surgical stripping, in terms of recurrence of varicose veins, Venous Clinical Severity Score (VCSS), pain and quality of life. Network meta-analysis and exploratory cost-effectiveness modelling were performed.

Results:
The literature search conducted in July 2011 identified 1453 unique citations: 34 RCTs (54 papers) satisfied the criteria for effectiveness review. Differences between treatments were negligible in terms of clinical outcomes, so the treatment with the lowest cost appears to be most cost-effective. Total FS costs were estimated to be lowest and it was marginally more effective than surgery. However, relative effectiveness was sensitive to the model time horizon. Threshold analysis indicated that EVLA and RFA might be considered cost-effective if their costs are similar to surgery. These findings are subject to various uncertainties, including the risk of bias present in the evidence base and variation in reported costs.

Conclusion:
This assessment of the currently available evidence suggests there is little to choose between surgery and the minimally invasive techniques in terms of efficacy or safety, so the relative
costs of the treatments becomes one of the deciding factors. High quality RCT evidence is needed to verify and further inform these findings.

**Introduction**

The prevalence of varicose veins in the UK has been reported to be between 20-40% in adults. The NHS performed over 33,000 surgical procedures in 2010-11 to treat varicose veins. However, the perceived low priority of varicose veins in economically straitened times may explain the recent reductions in varicose vein activity in England and Wales.\(^1\)

Conventional surgery (ligation and stripping) remains the most frequently performed procedure in the National Health Service (NHS)\(^2\)\(^3\) although there are regional variations in the type of procedures performed.\(^2\) However, ligation and stripping has been associated with a range of adverse effects such as wound infection, haematoma, lymph leaks, pain, scarring, nerve injury, Deep Vein Thrombosis (DVT) and long post-operative recovery.\(^4\)\(^7\) Conventional non-foam sclerotherapy, is considered faster but less effective than surgical stripping (hereafter, “surgery”).\(^8\)

The clinical signs and symptoms of venous disease may be classified using the CEAP classification: Clinical status; Etiology; Anatomy; and Pathophysiology.\(^9\)\(^11\) This ranges from C0 (no signs of venous disease) to C6 (active venous ulcer). C2 indicates varicose veins. The degree of severity of pain and other clinical signs or symptoms can be measured according to the Venous Clinical Severity Score (VCSS).\(^12\)\(^13\) The VCSS may be used to gauge clinical severity before and after intervention, i.e. to measure the efficacy of an intervention. The higher the score, the worse the disease severity. The presence of reflux is identified principally by duplex ultrasound (DUS). The criteria usually taken as indicating pathological reflux are the presence of venous flow reversal for >0.5 to 1.0 second with proximal compression, the Valsalva manoeuvre, or distal compression and release.\(^14\)

The principal outcomes associated with treatment for varicose veins are symptom relief and symptom severity, recurrence of varicosities, as well as the occurrence of new varicosities in
the same limb, and retreatment. Reported recurrence rates vary widely depending on the nature of the surgical technique performed and method of assessment. For conventional stripping and ligation surgery, two-year recurrence rates of up to 33% have been reported\cite{15,16}, rising to 41% for 5 years and to up to 70% at over 10 years.\cite{17,18} Surgical procedures for recurrence can therefore place considerable demand on the health services. Other outcomes of interest are health-related quality of life (HRQoL), patient treatment satisfaction, and the occurrence of related post-operative complications.

New minimally invasive treatments offer alternative methods of ablating incompetent veins, particularly the Greater Saphenous Vein. These treatments typically involve use of laser (endovenous laser ablation, EVLA)\cite{19}, radiofrequency probe (RFA)\cite{20} or foam sclerosant (FS).\cite{21} They are increasingly widely used and might offer potential benefits such as faster recovery, reduced complications, fewer physical limitations and increased HRQoL. In terms of active intervention, recent Guidance from the National Institute for Health and Care Excellence (NICE) recommends the use of EVLA or RFA; if this is considered "unsuitable", then FS should be used, and, if this technique is deemed "unsuitable", then surgery should be used.\cite{22} The study reported here was funded as a Health Technology Assessment report by the National Institute of Health Research (NIHR); the full detailed report is available elsewhere.\cite{23} It aimed to evaluate the clinical and cost effectiveness of the different minimally invasive methods of managing varicose veins compared with conventional surgery.

**Methods**

**Clinical effectiveness**

**Inclusion and exclusion criteria**
To be included in the review, a study had to be a randomised controlled trial (RCT) of adults aged 16 years or more who were being treated specifically for varicose veins and who received one of the following interventions (EVLA, RFA or FS). The comparator could be any of these treatments, surgery or conservative management. Outcomes included failure of the procedure, i.e. the procedure was incomplete; or occlusion or obliteration was not achieved or was not sustained for more than one month; technical recurrence (as distinct from initial episode), i.e. the presence of reflux, recanalisation or new varicose veins in a treated limb, diagnosed by duplex ultrasound scanning (DUS); Venous Clinical Severity Score
(VCSS); pain; time to return to work or normal activity; and post-operative complications (adverse events). Trials comparing different forms of the same intervention were excluded. Only the meta-analysed outcomes of technical recurrence, VCSS and pain are reported in this article.

**Search strategy and study selection**

A systematic review of the literature and (network) meta-analysis was undertaken in accordance with the general principles recommended in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. A comprehensive search was undertaken to identify systematically clinical effectiveness literature comparing different methods for the management of varicose veins. The search involved combining terms for the population (varicose veins) with terms for the interventions of interest, i.e. the minimally invasive techniques. The full search strategy is available in the full report. All searches were performed in July 2011. Eleven electronic databases were searched from inception for published and unpublished research evidence: MEDLINE, EMBASE, CINAHL, The Cochrane Library, Biological Abstracts, Science and Social Science Citation Indices, Conference Proceedings Citation Index- Science (CPCI-S), UK Clinical Trials Research Network (UKCRN), Current Controlled Trials and Clinical Trials.gov. All citations were imported into reference management software and titles and abstracts of all unique citations were screened independently by two reviewers using the inclusion criteria outlined below. Disagreements or queries were resolved by consensus or with reference to a third team member where necessary. The full papers of all potentially relevant citations were assessed for inclusion and reference-tracking of all included studies and relevant reviews was performed to identify additional, relevant studies not retrieved by the search of electronic databases.

**Data extraction, critical appraisal and synthesis**

Data extraction was performed by one reviewer into a standardised form and independently checked for accuracy by a second reviewer. Discrepancies were resolved by discussion. Critical appraisal of included trials was performed by one reviewer, using appropriate criteria adapted from a published checklist for surgical interventions, and independently checked for accuracy by a second. Discrepancies were resolved by discussion between reviewers. Blinding of patients and outcome assessors were not retained as criteria because the techniques generally did not permit such blinding, so the risk of detection bias was inherently high in all studies.
Methods of data synthesis

Technical recurrence, VCSS and pain score data were tabulated and, where data were appropriate, included studies were combined in a random-effects network meta-analysis, which allows for heterogeneity in treatment effects across studies. Randomisation and analysis in the primary studies was described as being by patient or by limb when patients were unilateral; when patients were bilateral, randomisation was by limb. Data were therefore all per limb or per patient; no data were per procedure (i.e. there were no data where multiple procedures were conducted on the same limb). The analysis was conducted using Markov chain Monte Carlo (MCMC) simulation implemented in the WinBUGS and OpenBugs software packages.25,26 The principal analysis compared the hazard of having technical recurrence when treating with EVLA, RFA and FS, relative to the common comparator of surgery using a complimentary log-log link function assuming that the underlying survivor functions follow Weibull distributions with separate shape and scale parameters to allow for the possibility of non-proportional hazards; a summary of the treatment effects is presented for 6 months, 1 year and 2 years. For VCSS and pain scores, the statistical model assumed a normal distribution for the observed sample means. Convergence of the models to their posterior distributions was assessed using the Brooks-Gelman-Rubin convergence statistic.27 Convergence occurred after 200,000 iterations for technical recurrence, after 10,000 iterations for VCSS and after 30,000 iterations for pain. Full details of the analysis are given elsewhere.23

Cost-effectiveness

Model Overview

The model was developed as a discrete event simulation (DES) model in Simul8® to simulate the experience of patients undergoing treatment for varicose veins. A DES model was chosen to allow non-constant hazard in the time to treatment failure/technical recurrence. This method also obviates the need for arbitrary time cycles. The baseline model had a perspective of ten years, chosen as a reasonable time over which to extrapolate the time to failure data. Costs were reported in 2011-12 British Pound Sterling; quality adjusted life years (QALYs) were used as the measure of effectiveness. The analysis took the perspective of the UK NHS and personal social services. All costs and benefits are discounted at a rate of 3.5%,
recommended NICE. Both probabilistic (PSA) and deterministic sensitivity analysis were undertaken.

**The model structure**

The model structure is illustrated in **Figure 1**. Ovals represent events (numbered 1 to 3) and oblongs health states (A to D). Treatments included in the model are surgery, FS, EVLA, and RFA (Event 1). Costs and a loss of utility from the short term adverse effects of treatment are assigned according to the treatment. Treatment may result in technical immediate (anatomical) success (states A and B) or failure (states C and D). If a failure, it is assumed that all patients will have further treatment with foam until technical success is achieved (Event 2). Patients with a successful clinical outcome nevertheless still have a probability of remaining symptomatic (state B). Thus initial treatment may result in one of two health states (A,B) based on the presence or absence of symptoms. Outcomes of varicose vein procedures are complex. Several disease-specific quality of life measures have been developed for varicose veins in recognition of the fact that whilst symptom relief is associated with clinical or anatomical outcomes, these are poor predictors of operative success from the patient’s perspective. For example, in a study of FS no correlation was found between changes in the Aberdeen Varicose Veins Questionnaire (AVVQ), a patient-reported measure of outcomes and quality-of-life, and venous refill times. Also, Merchant reports a high proportion of patients experiencing symptom improvement despite anatomical failure following RFA (70%-80%, compared to 85%-94% in limbs with anatomical success). In the model it was therefore not assumed that technical failure equates to the patient being symptomatic. Instead patients with technically successful and technically failed procedures have differing probabilities of being asymptomatic, with differing utility values attached to symptomatic and asymptomatic states. Patients may die at any time of all-cause mortality.

Adverse events, other than post-operative pain, are not included in the model because most adverse events of treatment, such as infection, haematoma, paraesthesia and phlebitis are relatively mild, of short duration and require no treatment. An exception is DVT, which can occasionally lead to death. However, the effectiveness review showed that DVT following treatment for varicose veins is very rare and so any possible effects on the model results were estimated to be negligible.

**Figure 1 here: Model structure**
Model Parameters

Uncertainty about parameters representing disease recurrence data and post-operative pain were sourced from the network meta-analysis (see Results). The proportion of patients requiring treatment for initial failure (treatment failure by one month) was determined from the time to failure distribution and top-up treatments for residual side branches and accessory saphenous veins estimated from additional meta-analysis of data from studies included in the effectiveness review. Both were assumed to be treated with FS. Studies varied in their use of phlebectomy concomitant with the primary procedure. In the model the initial procedure includes a proportion that would be undergoing concomitant phlebectomy in keeping with the trial evidence. Most used FS rather than phlebectomy for residual varicocities requiring secondary procedures unless there was recurrent incompetence. It was therefore assumed that 60% of late (after one month) retreatments were surgical procedures (stripping) and 40% FS.

The proportion of patients asymptomatic following a technically failed or successful procedure was taken from the literature. Procedure costs were derived from UK studies identified in a systematic search for economic studies of included treatments. However, only the cost of surgery was available from more than one study and was quite variable, ranging from £660 to £1,420 at 2011/12 prices. The cost for surgery was therefore taken from National Reference costs, but these do not differentiate between the other treatment methods. The cost of other treatments relative to surgery was published only in a small number of studies, so this information had to be used to calculate their cost, as shown Figure 2. The costs of EVLA were estimated from those for RFA, based on additional equipment costs. To address variation in treatment costs a threshold analysis was performed to determine the cost at which the minimally invasive treatments might be considered cost-effective. Resource use (GP and outpatient visits, duplex scan) associated with retreatment were estimated and costed using standard sources.

To derive an estimate of the utility associated with symptomatic varicose veins a meta-analysis was undertaken of all studies reporting baseline (pre-treatment) EQ-5D in this population. Six relevant studies were identified with 1177 unique patients. Age-independent estimates were calculated by dividing the reported values by the population average utility for the mean study population ages. This gave a utility value of 0.88 (se 0.009) for patients with symptomatic varicose veins. Asymptomatic patients are assumed to have the same utility as the general population of their age, so the state utility value is one. In the model age-specific utility is calculated by multiplying the state utility by the age-dependent utility. Loss of utility associated with post-operative pain was estimated from a
single study reporting both. The reduction in EQ-5D utility for each absolute 1% increase in VAS pain score was 0.0026. All parameter values are reported in Supplementary Data Table S1 except time to recurrence (see Figure 8 in Results section).

Figure 2 here: Initial procedure costs estimated relative to surgery costs

Results

Clinical effectiveness review

Included studies

The searches identified 1453 unique citations. See the PRISMA flowchart below (Figure 3). Eleven citations represented relevant ongoing trials and 51 citations, representing 31 different studies, provided data used in the network meta-analyses. Study characteristics for these trials are shown in Table S2 (supplementary information). Fourteen trials evaluated EVLA against surgery, RFA or FS; thirteen trials compared RFA with surgery, EVLA, FS or other comparators; and thirteen trials evaluated FS, principally comparing it with conventional surgery. One trial had arms comparing all three minimally invasive techniques. No trial included conservative management as a comparator. The principal, common comparator was surgery, i.e. ligation and stripping.

3873 participants were reported as randomised across all trials. The number of randomised participants in a single trial ranged from 28 to 710. The mean age of participants ranged from 33 to 54 years. There was a majority of female participants in every trial; the percentage of female participants ranged from 54% to 95%. In all trials participants were required to have varicose veins diagnosed by duplex scanning and categorised according to the CEAP score. The vast majority of participants in any trial were C2 on the CEAP score (varicose veins), except for three trials, where the majority were C3, C4 or C5. The UK was the single most frequent location (12 trials); the remainder were conducted in centres across thirteen other different countries.

Quality of included studies
The methodological quality assessment of each included study is summarised in Table S3 (supplementary information). The majority of the trials used in the network meta-analyses (e.g. those reporting technical recurrence data for EVLA versus surgery or EVLA versus RFA etc.) were at risk of either selection or attrition bias due to inadequate randomisation, allocation concealment or intention-to-treat analysis. Only four of the included trials actually reported that surgeons were sufficiently experienced across arms in the various procedures, thus reducing the likelihood of bias resulting from performance of the various techniques.\textsuperscript{61,63,65,73}

**Recurrence**

The principal outcome reported by trials was technical recurrence, as defined above. Data were available from 23 trials at various follow-up times.\textsuperscript{41,43-49,51-56,61,72-77} The results suggested that there was mild heterogeneity between studies in the shape parameter (0.17; 95% CrI: 0.01, 0.45) but that there was mild to moderate heterogeneity between studies in the scale parameter (0.26; 95% CrI: 0.02, 0.91). EVLA exhibited the lowest rates of technical recurrence relative to surgery, although there was some evidence that this benefit decreases over time (2 Year HR, 0.84; 95% CrI: 0.44, 1.81) (see Figure 4). RFA was associated with a small and relatively constant lower rate of technical recurrence over time compared with surgery (2 Year HR, 0.94; 95% CrI: 0.42, 2.51). FS was worse than surgery over the first year, although there was a small benefit after two years (2 Year HR, 0.92; 95% CrI: 0.43, 1.60). In each case there was considerable uncertainty about which intervention was the most beneficial.

**Figure 4 here: Technical recurrence**

**Venous Clinical Severity Score (VCSS)**

Thirteen studies met the inclusion/exclusion criteria for VCSS as an outcome, although 1 year data was available from only 6 studies.\textsuperscript{53,46,57,63,66,78} The between study standard deviation (SD) was estimated to be 0.22, which is indicative of mild to moderate heterogeneity in treatment effect between studies (95% CrI: 0.01, 1.79). The VCSS for both FS and EVLA were lower than for surgery, i.e. patients and clinicians reported fewer clinical symptoms for these treatments compared to surgery. (See Figure 5).

**Figure 5 here: VCSS**
**Pain score**

Eleven trials reported measuring pain using a form of visual analogue scale (1-10 or 1-100) for a period between three and 14 days post-operation and were included in the network meta-analysis.\textsuperscript{41,45,53,56-59,61,63,64,79} The between study standard deviation was estimated to be 0.48; (95% CrI: 0.06, 1.12), which is indicative of mild to moderate heterogeneity in treatment effect between studies. The interventions that exhibited the lowest pain scores compared to surgery were RFA (mean difference, -1.26 95% CrI: -1.95, -0.61) and FS (mean difference, -0.80 95% CrI: -1.93, 0.30). (See Figure 6)

**Figure 6 here:** Pain scores

**Adverse events**

In general, serious adverse events, such as DVT or pulmonary embolism (PE) were rare. Eleven studies reported on these outcomes but only five studies reported that any such complication actually occurred.\textsuperscript{46,48,56,80} The three trials reporting the highest numbers of these adverse events, i.e. Wright\textsuperscript{78}, Rasmussen et al., 2011\textsuperscript{87} and Shadid et al.,\textsuperscript{125} also had the largest sample sizes of all included studies in the review\textsuperscript{48,56,80}, with Wright et al\textsuperscript{48} reporting a substantially higher rate than any other study. However, this disproportionate rate can be explained by the intervention. The “VARISOLVE®” technique (BTG, London, UK) applied in this trial was new and the amount of foam used was altered part way through the trial because of the high DVT rate: the initial amount of foam (60mL) was reduced to 30mL. No DVT was reported for the 95 participants who subsequently received this lower dose.

**Summary of effectiveness**

The analysis of the technical recurrence data suggested that the benefit of treatment with EVLA and FS varied over time. In particular, the early benefit associated with EVLA relative to surgery was less at 2 years than at 6 months. However, the results were inconclusive in determining which intervention was the most effective. The analysis of the VCSS data suggested that FS was the most effective intervention. The analysis of the pain score data suggested that RFA was the most effective treatment.

**Cost-effectiveness**
The results of the PSA analysis, with costs and QALYs discounted at a rate of 3.5%, are shown in Figure 7. Although there is an element of retreatment, the total costs of treatment are primarily comprised of the initial treatment cost, with RFA the most expensive procedure and FS the least costly option. All of the minimally invasive treatments result in more QALYs compared to surgery at 10 years, but the QALY differences between surgery, EVLA and RFA are negligible: equivalent to less than a day in full health for EVLA compared to surgery.

**Figure 7 here: Results of the discounted PSA economic analysis**

Foam is less costly than surgery and marginally more effective, and can thus be said to dominate surgery. The probability of it being the most cost-effective treatment is above 90% for willingness to pay thresholds in the range £20,000 to £50,000. The Incremental Cost Effectiveness Ratios (ICERs) for EVLA and RFA, in comparison to surgical stripping, show they are not cost-effective at usually accepted levels.28

The full results of the univariate sensitivity analysis are reported elsewhere.23 The results were not sensitive to uncertainty associated with most parameters, with the exception of the disutility associated with post-operative treatment, and the model time horizon. The results for FS compared to surgery were potentially sensitive to disutility associated with treatment, a parameter derived from the network meta-analysis of reported pain at approximately 10 days (see Figure 6). By 10 days post-operative pain has already subsided, and therefore the analysis may not fully reflect differences between the treatments. Also the relationship between post-operative pain and utility was based on limited data.43

The model time horizon has the potential to affect results due to differences between the treatments in post-operative pain and recurrence rates. (See Figures 4 and 8) For EVLA and RFA the incremental QALYs are greater and the costs lower with increasing timespan as their failure rates are lower than for surgery (Hazard ratio [HR] at one year 0.77 for EVLA, 0.93 for RFA), so the ICERs are lower the longer the model time horizon, but even run for a lifetime the ICERs do not approach £30,000. RFA results in less post-operative pain than EVLA, so RFA results in more QALYs at two years compared to EVLA, but by 10 years EVLA has overtaken RFA due to lower failure rates. For FS the picture is more complex. The
pain associated with treatment is lower than for surgery, resulting initially in higher QALYs. However the rate of failure is slightly higher in the first few years compared to surgery (HR foam 1.02 at one year) potentially resulting in fewer QALYs for intermediate model timespans. In the long term (between 10 years and life) foam has a lower failure rate than surgery and leads to a small QALY gain.

**Figure 8 here: Probability of technical recurrence by intervention (mean)**

**Summary of cost-effectiveness**

Differences between treatments are negligible in terms of clinical outcomes, so the treatment with the lowest cost appears to be most cost-effective. Our central estimate is that total FS costs are the lowest and it is marginally more effective than surgical stripping (+0.0015 QALYs), with a probability of being the most cost-effective treatment above 90% for willingness-to-pay thresholds in the range £20,000–50,000. This result is, however, sensitive to the model time horizon (i.e. cost-effectiveness is reduced in the shorter term because of the early failure rates for this technique). EVLA and RFA both cost more than surgery, and with very little difference in QALYs they cannot be considered cost-effective at the usual threshold of £20,000–30,000, a result that is robust to parameter variation and model time horizon. There is considerable uncertainty in the cost differences between treatments arising from different reported costs of the procedures, and in fact these are likely to vary with setting, and may also vary over time. Threshold analysis showed that the additional costs of EVLA and RFA would have to be not more than £50 and £24 more than surgery, respectively, to be considered cost-effective at a threshold of £20,000.23

**Discussion**

This assessment of the evidence published up to August 2011 suggests there is little to choose between the minimally invasive techniques in terms of efficacy or cost, and each offers a viable, clinically effective alternative to stripping. FS might offer the most cost-effective alternative to stripping, within certain time parameters, although there is some uncertainty over the longer-term benefits. EVLA and RFA both cost more than surgery, and with very little difference in QALYs they cannot be considered cost-effective at the usual threshold of
However, there was limited cost data for the procedures apart from surgery, where reported costs were quite variable. Cost differences between treatments are therefore highly uncertain. EVLA and RFA were marginally more effective than surgery so if their costs were similar to surgery they would be considered cost-effective. In view of the small absolute differences in costs and outcomes between the techniques, other issues of importance to patients, such as the less invasive nature of some options, the opportunity to avoid larger scars and general anaesthesia may be important in the choice of procedure. Furthermore, if wider social benefits, such as speed of recovery and return to work, were to be considered in costs, then the minimally invasive techniques might demonstrate further benefits over surgery, the majority of studies evaluating time to return to work or normal activity report a significant reduction for the minimally invasive techniques compared to surgical stripping.23

All of the effectiveness analyses presented here used only technical rather than symptomatic recurrence data, so the true proportion of treated individuals who are likely to present with symptoms of recurrence requiring retreatment is not certain. The rates of technical recurrence reported here are therefore higher than those encountered in clinical practice because non-symptomatic patients would not present, even if they were experiencing technical recurrence. The findings on initial failure and retreatment, symptomatic recurrence and retreatment for recurrence, given in the full report23, are affected by a high degree of uncertainty due to the relative infrequency with which such data were reported, as well as the limitations of the primary studies’ reporting of these data. Based on projections from trial data the long-term risk of a technical recurrence is less for all the minimally invasive treatments compared with surgery, although the time to treatment failure curves are quite similar.

The cost-effectiveness model shows that any differences in benefits (QALYs) between the different procedures are negligible, but marginally favour the minimally invasive treatments relative to surgery. Disutility associated with post-operative pain, although not severe and limited to a few days duration, affects the results in the short term (two years), demonstrating the limited effects of time to failure on differential QALYs. There are differences in treatment costs however and, with little differences in QALYs, incremental net benefits are primarily driven by costs. The model results are consistent with other studies in finding that QALY differences between treatments are very small.82,83 That of Gohel is also a modelling study comparing different treatments for varicose veins.82 However, in other respects the results of this model are different. Gohel estimated the costs of treatments from basic units of resource
(day case, outpatient, equipment costs) and reports day case surgery to be more costly than any of the minimally invasive treatments, contrary to more recently published cost studies showing the costs of EVLA and RFA to be greater than those for surgery. Gohel also finds surgery to be more effective than the minimally invasive treatments, on the basis of much more limited effectiveness data than used in the current analysis.

The new treatments have additional implications for training and the availability of equipment. It is possible that there are learning curve effects because the technology is continuing to develop and there are various options for some aspects of the treatment, such as timing and dosage of energy exposure, which are continuing to be investigated. Some of the earlier studies used devices or techniques that have already been superseded and it is possible that greater experience and more widespread adoption will result in improved outcomes and reduced complications. However, there may also be issues of the availability of the necessary skills and equipment, with the resource implications of providing training in the new methods.

The overall results of this research differ from the findings of other published systematic reviews and meta-analyses in their conclusion that FS, EVLA and RFA offer potentially equally effective alternatives to surgery and, in the case of FS, a cost-effective alternative also. This difference can be explained by the inclusion of more RCT evidence in the present report (approximately three times as many relevant RCTs than any previous review, despite broader criteria in the majority of the previous reviews), the exclusion of non-RCT and non-comparative evidence, and the analysis methods used. The recently published clinical practice guidelines from both NICE and the Society for Vascular Surgery and American Venous Forum also recommend EVLA, RFA and FS as effective alternatives to surgery and other modalities, but the latter only cites a small number of RCTs with short-term follow-up, and one or two of the reviews cited here. Also, recent NICE guidance recommends EVLA and RFA, if suitable, as initial treatment, before using FS or surgery, although this report has found that FS is potentially the most cost-effective treatment over longer time horizons. None of the previously published reviews or analyses acknowledged the limitation presented by the use of technical recurrence evidence, rather than symptomatic technical recurrence as an outcome.

Other than the limitations of the technical recurrence data, the principal uncertainties affecting the analyses are in the cost differentials between treatments, which are likely to vary with setting, and may vary over time. There was very limited data on the costs of the different
procedures, but threshold analysis showed that the additional costs of EVLA and RFA would have to be not more than £50 and £24 more than surgery, respectively, to be considered cost-effective at a threshold of £20,000. The differences in clinical effectiveness (time to recurrence, post-operative pain) were small. The vast majority of the trials were conducted in Western Europe in populations who would typically present in the UK with varicose veins and be treated with one of the modalities assessed, so the external validity of the evidence is relatively strong for the NHS.

This assessment of the evidence suggests there is little to choose between the minimally invasive techniques in terms of technical recurrence, VCSS, pain and adverse events, and each offers a viable, clinically effective alternative to surgical stripping. Foam sclerotherapy might offer the most cost-effective alternative to surgery, within certain time parameters. Training and experience in the minimally invasive techniques might be required before relative benefits are apparent. Future trials should aim to measure and report outcomes in a standardised manner, which would permit more efficient pooling of their results, e.g. mean and Standard Deviation (SD) of all validated and commonly-used measures, such as VCSS and EQ-5D. Trial authors should also report both technical and symptomatic recurrence, to permit assessment of likely retreatment rates and costs, and utilise surgeons with adequate experience of the minimally invasive techniques, if the comparison with surgery (currently the most common procedure performed by all surgeons) is to be internally valid.
Figure 1: Model structure

Figure 2: Initial procedure costs estimated relative to surgery costs (31;32;34)

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Cost relative to surgery</th>
<th>Initial procedure cost</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgery</td>
<td>-</td>
<td>£1,155</td>
<td>National reference costs</td>
</tr>
<tr>
<td>Foam sclerotherapy</td>
<td>0.55</td>
<td>£634</td>
<td>Bontourouglo 2006</td>
</tr>
<tr>
<td>RFA</td>
<td>2.28</td>
<td>£2,635</td>
<td>Subramonia 2010</td>
</tr>
<tr>
<td>EVLA</td>
<td>2.02</td>
<td>£2,338</td>
<td>See text</td>
</tr>
</tbody>
</table>
Figure 3: PRISMA flowchart

Records identified through database searching (n = 1453)
Additional records identified through other sources (n = 2)

Records screened by title and abstract (n = 1455)

Excluded by title and abstract (n = 1343)

Full-text articles (references) assessed for eligibility (n = 112)

Full-text articles excluded, with reasons (n = 58)
- Not RCT (n = 28)
- RCT of comparator interventions (n = 3)
- Non-relevant outcomes (n = 3)
- RCT of a co-intervention (n = 1)
- Letters (n = 4)
- Duplicate (n = 4)
- Not available (n = 1)
- Published later as full paper (n = 1)

Full text articles included (n = 54 citations; 34 studies)

Studies included in quantitative synthesis (meta-analysis)
(n = 31 studies; 51 citations)
Figure 4: Technical recurrence: Posterior distribution for the hazard ratios relative to surgery at 6 months, 1 year and 2 years

<table>
<thead>
<tr>
<th></th>
<th>6 Months</th>
<th>1 Year</th>
<th>2 years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Median</td>
<td>Median</td>
<td>Median</td>
</tr>
<tr>
<td></td>
<td>(95% CrI)</td>
<td>(95% CrI)</td>
<td>(95% CrI)</td>
</tr>
<tr>
<td></td>
<td>[Probability HR &gt;1]</td>
<td>[Probability HR &gt;1]</td>
<td>[Probability HR &gt;1]</td>
</tr>
<tr>
<td>EVLA vs. surgery</td>
<td>0.70 (0.27, 1.45)</td>
<td>0.77 (0.37, 1.54)</td>
<td>0.84 (0.44, 1.81)</td>
</tr>
<tr>
<td></td>
<td>0.150</td>
<td>0.182</td>
<td>0.257</td>
</tr>
<tr>
<td>RFA vs. surgery</td>
<td>0.92 (0.39, 2.11)</td>
<td>0.93 (0.42, 2.22)</td>
<td>0.94 (0.42, 2.51)</td>
</tr>
<tr>
<td></td>
<td>0.409</td>
<td>0.411</td>
<td>0.421</td>
</tr>
<tr>
<td>FS vs. surgery</td>
<td>1.12 (0.53, 2.27)</td>
<td>1.02 (0.49, 1.84)</td>
<td>0.92 (0.43, 1.60)</td>
</tr>
<tr>
<td></td>
<td>0.659</td>
<td>0.524</td>
<td>0.359</td>
</tr>
</tbody>
</table>

Technical recurrence: the presence of reflux, recanalisation or new varicose veins in a treated limb, diagnosed by duplex ultrasound scanning (DUS); CrI: Credible interval; HR: Hazard ratio; EVLA: Endovenous laser ablation; RFA: Radiofrequency ablation; FS: Foam sclerotherapy

Figure 5: VCSS: Posterior distribution for the mean difference compared to surgery

<table>
<thead>
<tr>
<th></th>
<th>Median (95% CrI)</th>
<th>Probability of mean difference &gt;0</th>
</tr>
</thead>
<tbody>
<tr>
<td>EVLA vs. surgery</td>
<td>-0.10 (-0.94, 0.73)</td>
<td>0.324</td>
</tr>
<tr>
<td>RFA vs. surgery</td>
<td>0.15 (-0.50, 0.95)</td>
<td>0.739</td>
</tr>
<tr>
<td>FS vs. surgery</td>
<td>-1.63 (-2.90, -0.42)</td>
<td>0.015</td>
</tr>
</tbody>
</table>

CrI: Credible interval; EVLA: Endovenous laser ablation; RFA: Radiofrequency ablation; FS: Foam sclerotherapy
Figure 6: Pain scores: Posterior distribution for the mean difference compared to surgery

<table>
<thead>
<tr>
<th></th>
<th>Median (95% CrI)</th>
<th>Probability of mean difference &gt;0</th>
</tr>
</thead>
<tbody>
<tr>
<td>EVLA vs. surgery</td>
<td>0.10 (-0.49, 0.64)</td>
<td>0.653</td>
</tr>
<tr>
<td>RFA vs. surgery</td>
<td>-1.26 (-1.95, -0.61)</td>
<td>0.001</td>
</tr>
<tr>
<td>FS vs. surgery</td>
<td>-0.80 (-1.93, 0.30)</td>
<td>0.062</td>
</tr>
</tbody>
</table>

Crl: Credible interval; EVLA: Endovenous laser ablation; RFA: Radiofrequency ablation; FS: Foam sclerotherapy

Figure 7: Results of the discounted Probabilistic Sensitivity Analysis. An economic analysis of treatments for varicose veins

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Discounted Costs</th>
<th>Discounted QALYS</th>
<th>Incremental Costs</th>
<th>Incremental QALYS</th>
<th>ICER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgery</td>
<td>£1,334</td>
<td>8.0347</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Foam</td>
<td>£804</td>
<td>8.0362</td>
<td>-£530</td>
<td>0.0015</td>
<td>NA</td>
</tr>
<tr>
<td>EVLA</td>
<td>£2,637</td>
<td>8.0372</td>
<td>£1,302</td>
<td>0.0025</td>
<td>£518,462</td>
</tr>
<tr>
<td>RFA</td>
<td>£2,952</td>
<td>8.0359</td>
<td>£1,617</td>
<td>0.0012</td>
<td>£1,352,992</td>
</tr>
</tbody>
</table>

ICER: Incremental cost effectiveness ratio
Figure 8: Probability of technical recurrence by intervention (mean)

![Graph showing the probability of technical recurrence by intervention over time. The x-axis represents time in years, ranging from 0 to 10. The y-axis represents the probability of no recurrence, ranging from 0.0 to 1.0. There are different lines for each intervention: Surgery (solid black), EVLA (dashed red), RFA (dotted green), and Foam sclerotherapy (dashed blue).]
Reference List


(68) Abela R, Liamis A, Prionidis I, Mathai J, Gorton L, Browne T et al. Reverse foam sclerotherapy of the great saphenous vein with sapheno-femoral ligation compared to


